Wednesday, March 10, 2021 Daily Archives

Expanding Applications in Downstream Biologics Characterization: Stability, Formulations and Aggregation Studies using Octet®

by

Structure is an important characteristic for protein activity and function. Structural alterations due to protein mis-folding, denaturation or unfavorable conditions can lead to the formation of aggregate species that can affect the efficacy and safety of biologic drug candidates. While many biophysical analytical tools are well suited for detecting these aggregates, few offer a combination of structural and functions assessment in the same system. Sartorius’ Octet® platform is an easy-to-use analytical tool that can detect the presence of aggregated species…

March 10, 2021

Novartis: Kundl shines bright for CureVac’s COVID vaccine

by

Novartis has invested €20 million ($23.8m) to service the CureVac deal and says up to 100 jobs will be created at its Kundl site in Austria.   Last week, Novartis became the latest firm to partner with CureVac to help manufacture its COVID-19 candidate, CVnCoV, at Novartis’ site in Kundl, Austria. The firm plans to manufacture up to 50 million doses by the end of 2021 and, potentially, a further 200 million doses by 2022. A spokesperson for Novartis told…

March 10, 2021

Exelixis inks deal with WuXi Bio as it advances ADC ambition

by

“We really like the ADC space,†says Exelixis as it licenses a panel of monoclonal antibodies from WuXi Biologics. Californian pharma firm Exelixis has paid what it describes as a “modest†upfront payment to Chinese drugmaker WuXi Biologics for the exclusive license of a panel of monoclonal antibodies to a preclinically validated target for the development of antibody-drug conjugates (ADCs), bispecifics, and other biologic applications. “Our agreement with WuXi Bio enhances our growing biotherapeutics portfolio by providing an approach to…

March 10, 2021

Podcast: Content is king in bioprocessing and beyond

by

In the latest episode of the BioProcess Insider Expression System, Brian Caine (remember him) talks content, marketing, and communications in the biomanufacturing industry. Brian Caine, founder and publisher of our parent publication BioProcess International, stepped down from his position late last year to pursue new ventures. After a quarter of a century in the life sciences space, he speaks to us about the evolving publishing landscape and while he stresses ‘content is king,’ he warns that you cannot just print…

March 10, 2021